These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 30505706)

  • 1. A scalable solution for tumor mutational burden from formalin-fixed, paraffin-embedded samples using the Oncomine Tumor Mutation Load Assay.
    Chaudhary R; Quagliata L; Martin JP; Alborelli I; Cyanam D; Mittal V; Tom W; Au-Young J; Sadis S; Hyland F
    Transl Lung Cancer Res; 2018 Dec; 7(6):616-630. PubMed ID: 30505706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.
    Endris V; Buchhalter I; Allgäuer M; Rempel E; Lier A; Volckmar AL; Kirchner M; von Winterfeld M; Leichsenring J; Neumann O; Penzel R; Weichert W; Glimm H; Fröhling S; Winter H; Herth F; Thomas M; Schirmacher P; Budczies J; Stenzinger A
    Int J Cancer; 2019 May; 144(9):2303-2312. PubMed ID: 30446996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Robust assessment of tumor mutational burden in cytological specimens from lung cancer patients.
    Alborelli I; Bratic Hench I; Chijioke O; Prince SS; Bubendorf L; Leuenberger LP; Tolnay M; Leonards K; Quagliata L; Jermann P; Matter MS
    Lung Cancer; 2020 Nov; 149():84-89. PubMed ID: 32980613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project.
    Merino DM; McShane LM; Fabrizio D; Funari V; Chen SJ; White JR; Wenz P; Baden J; Barrett JC; Chaudhary R; Chen L; Chen WS; Cheng JH; Cyanam D; Dickey JS; Gupta V; Hellmann M; Helman E; Li Y; Maas J; Papin A; Patidar R; Quinn KJ; Rizvi N; Tae H; Ward C; Xie M; Zehir A; Zhao C; Dietel M; Stenzinger A; Stewart M; Allen J;
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-cancer-gene Panel.
    Zhuang W; Ma J; Chen X; Wang G; Lu J; Chen Y; Dong H; Cai S; Zhang Y; Zhao X; Zhu Y; Xu C; Huang Y; Huang Z; Zhu X; Jiang H; Wang Z
    J Cancer; 2018; 9(13):2302-2307. PubMed ID: 30026825
    [No Abstract]   [Full Text] [Related]  

  • 6. Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST).
    Astolfi A; Urbini M; Indio V; Nannini M; Genovese CG; Santini D; Saponara M; Mandrioli A; Ercolani G; Brandi G; Biasco G; Pantaleo MA
    BMC Genomics; 2015 Nov; 16():892. PubMed ID: 26531060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer.
    Chang H; Sasson A; Srinivasan S; Golhar R; Greenawalt DM; Geese WJ; Green G; Zerba K; Kirov S; Szustakowski J
    Mol Diagn Ther; 2019 Aug; 23(4):507-520. PubMed ID: 31250328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA Sequencing Data for FFPE Tumor Blocks Can Be Used for Robust Estimation of Tumor Mutation Burden in Individual Biosamples.
    Sorokin M; Gorelyshev A; Efimov V; Zotova E; Zolotovskaia M; Rabushko E; Kuzmin D; Seryakov A; Kamashev D; Li X; Poddubskaya E; Suntsova M; Buzdin A
    Front Oncol; 2021; 11():732644. PubMed ID: 34650919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of a Targeted Next-Generation Sequencing Panel for Tumor Mutation Burden Analysis: Results from the Onconetwork Immuno-Oncology Consortium.
    Fenizia F; Alborelli I; Costa JL; Vollbrecht C; Bellosillo B; Dinjens W; Endris V; Heydt C; Leonards K; Merkelback-Bruse S; Pfarr N; van Marion R; Allen C; Chaudhary R; Gottimukkala R; Hyland F; Wong-Ho E; Jermann P; Machado JC; Hummel M; Stenzinger A; Normanno N
    J Mol Diagn; 2021 Jul; 23(7):882-893. PubMed ID: 33964449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples.
    Bonfiglio S; Vanni I; Rossella V; Truini A; Lazarevic D; Dal Bello MG; Alama A; Mora M; Rijavec E; Genova C; Cittaro D; Grossi F; Coco S
    BMC Cancer; 2016 Aug; 16(1):692. PubMed ID: 27578032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Three Sequencing Panels Used for the Assessment of Tumor Mutational Burden in NSCLC Reveals Low Comparability.
    Heeke S; Benzaquen J; Hofman V; Long-Mira E; Lespinet V; Bordone O; Marquette CH; Delingette H; Ilié M; Hofman P
    J Thorac Oncol; 2020 Sep; 15(9):1535-1540. PubMed ID: 32450274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Tumor Mutational Burden in Pediatric Tumors by Real-Life Whole-Exome Sequencing and In Silico Simulation of Targeted Gene Panels: How the Choice of Method Could Affect the Clinical Decision?
    Noskova H; Kyr M; Pal K; Merta T; Mudry P; Polaskova K; Ivkovic TC; Adamcova S; Hornakova T; Jezova M; Kren L; Sterba J; Slaby O
    Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31963488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making.
    De Paoli-Iseppi R; Johansson PA; Menzies AM; Dias KR; Pupo GM; Kakavand H; Wilmott JS; Mann GJ; Hayward NK; Dinger ME; Long GV; Scolyer RA
    Pathology; 2016 Apr; 48(3):261-6. PubMed ID: 27020503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project.
    Vega DM; Yee LM; McShane LM; Williams PM; Chen L; Vilimas T; Fabrizio D; Funari V; Newberg J; Bruce LK; Chen SJ; Baden J; Carl Barrett J; Beer P; Butler M; Cheng JH; Conroy J; Cyanam D; Eyring K; Garcia E; Green G; Gregersen VR; Hellmann MD; Keefer LA; Lasiter L; Lazar AJ; Li MC; MacConaill LE; Meier K; Mellert H; Pabla S; Pallavajjalla A; Pestano G; Salgado R; Samara R; Sokol ES; Stafford P; Budczies J; Stenzinger A; Tom W; Valkenburg KC; Wang XZ; Weigman V; Xie M; Xie Q; Zehir A; Zhao C; Zhao Y; Stewart MD; Allen J;
    Ann Oncol; 2021 Dec; 32(12):1626-1636. PubMed ID: 34606929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Preanalytical Factors and Tumor Mutational Burden Estimated by Next-Generation Sequencing-Based Multiplex Gene Panel Assay.
    Quy PN; Kanai M; Fukuyama K; Kou T; Kondo T; Yamamoto Y; Matsubara J; Hiroshima A; Mochizuki H; Sakuma T; Kamada M; Nakatsui M; Eso Y; Seno H; Masui T; Takaori K; Minamiguchi S; Matsumoto S; Muto M
    Oncologist; 2019 Dec; 24(12):e1401-e1408. PubMed ID: 31186376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients.
    Heeke S; Benzaquen J; Long-Mira E; Audelan B; Lespinet V; Bordone O; Lalvée S; Zahaf K; Poudenx M; Humbert O; Montaudié H; Dugourd PM; Chassang M; Passeron T; Delingette H; Marquette CH; Hofman V; Stenzinger A; Ilié M; Hofman P
    Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31470674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens.
    Parikh K; Huether R; White K; Hoskinson D; Beaubier N; Dong H; Adjei AA; Mansfield AS
    JAMA Netw Open; 2020 Feb; 3(2):e200202. PubMed ID: 32108894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of low tumor content on tumor mutational burden estimation by whole-exome sequencing and targeted panel sequencing.
    Zhang W; Wang R; Fang H; Ma X; Li D; Liu T; Chen Z; Wang K; Hao S; Yu Z; Chang Z; Na C; Wang Y; Bai J; Zhang Y; Chen F; Li M; Chen C; Wei L; Li J; Chang X; Qu S; Yang L; Huang J
    Clin Transl Med; 2021 May; 11(5):e415. PubMed ID: 34047470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Novel Reference Material for Tumor Mutational Burden Measurement Based on CRISPR/Cas9 Technology.
    Peng R; Lin G; Li L; Li J
    Front Oncol; 2022; 12():845636. PubMed ID: 35574377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.
    Fabrizio DA; George TJ; Dunne RF; Frampton G; Sun J; Gowen K; Kennedy M; Greenbowe J; Schrock AB; Hezel AF; Ross JS; Stephens PJ; Ali SM; Miller VA; Fakih M; Klempner SJ
    J Gastrointest Oncol; 2018 Aug; 9(4):610-617. PubMed ID: 30151257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.